24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
BORTELIEVA 3.5MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | BORTELIEVA 3.5MG |
|---|---|
| Composition | Bortezomib Injection IP 3.5mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
BORTELIEVA 3.5MG (Bortezomib Injection IP 3.5mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
BORTELIEVA 3.5 MG (Bortezomib Injection IP 3.5 mg) is a prescription anticancer medicine containing Bortezomib 3.5 mg, a targeted therapy used primarily for the treatment of Multiple Myeloma and Mantle Cell Lymphoma (MCL). Bortezomib belongs to a class of medicines known as proteasome inhibitors, which work by disrupting important cellular processes within cancer cells, leading to their destruction while helping slow disease progression.
Multiple Myeloma is a type of blood cancer that develops in plasma cells, a specialized type of white blood cell responsible for producing antibodies. When these cells become cancerous, they multiply uncontrollably and can damage bones, kidneys, and the immune system. Mantle Cell Lymphoma is a rare and aggressive form of non-Hodgkin lymphoma that affects lymphocytes within the lymphatic system. BORTELIEVA 3.5 MG is designed to target these abnormal cancer cells and help improve treatment outcomes.
Bortezomib works by blocking proteasomes, which are structures inside cells responsible for breaking down unwanted proteins. Cancer cells depend heavily on proteasomes for survival and rapid growth. When proteasome activity is inhibited, damaged proteins accumulate within cancer cells, triggering stress and ultimately causing cell death. This targeted mechanism makes Bortezomib an important therapy in modern hematology and oncology practice.
BORTELIEVA 3.5 MG is commonly prescribed for:
The medicine may be administered alone or in combination with other anticancer agents depending on the patient's condition, treatment history, and therapeutic goals.
Manufactured under stringent pharmaceutical quality standards, BORTELIEVA 3.5 MG is designed to deliver consistent quality, safety, and therapeutic effectiveness. The injection should only be administered by qualified healthcare professionals experienced in oncology and hematology treatment.
Patients receiving Bortezomib therapy often require routine blood tests, liver function monitoring, kidney assessments, neurological evaluations, and regular clinical follow-up to ensure safe and effective treatment.
Due to its proven efficacy in blood cancer treatment, BORTELIEVA 3.5 MG remains an essential medicine in modern oncology care worldwide.
BORTELIEVA 3.5 MG (Bortezomib Injection IP 3.5 mg) is primarily used for the treatment and management of specific blood cancers.
The medicine is widely used in patients diagnosed with newly diagnosed or relapsed multiple myeloma.
Bortezomib is approved for the treatment of mantle cell lymphoma in selected patients.
The medicine may be used when blood cancers return after previous treatment.
BORTELIEVA is frequently combined with other anticancer medicines to improve treatment outcomes.
The medicine supports comprehensive treatment strategies for complex blood cancers.
It plays an important role in modern targeted cancer therapy protocols.
Bortezomib belongs to a class of medicines known as Proteasome Inhibitors.
BORTELIEVA works by:
This targeted mechanism helps control disease progression and improve therapeutic outcomes in blood cancer patients.
Like all anticancer medicines, BORTELIEVA 3.5 MG may cause side effects in some patients. Side effects vary depending on dosage, treatment duration, and individual patient response.
Weakness and tiredness are commonly reported during treatment.
Patients may experience mild to moderate nausea.
Episodes of vomiting may occur in some individuals.
Digestive disturbances and loose stools may develop.
Some patients may experience difficulty passing stools.
Reduced appetite may affect nutritional intake.
Mild fever may occur during treatment.
Patients may experience tingling, numbness, or pain in the hands and feet.
The medicine may reduce:
This may increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of BORTELIEVA 3.5 MG (Bortezomib Injection IP 3.5 mg) should always be determined by a qualified oncologist or hematologist.
Treatment schedules vary according to the diagnosed condition.
Dosage is commonly calculated according to body size.
Prior cancer treatments may influence therapy planning.
Laboratory results help determine treatment suitability.
Doctors may adjust therapy based on effectiveness and tolerability.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of Multiple Myeloma and Mantle Cell Lymphoma.
Bortezomib is a proteasome inhibitor that disrupts cancer cell survival and promotes cancer cell death.
It is considered a targeted anticancer therapy and is commonly used in oncology treatment programs.
Yes, it is frequently administered as part of combination treatment regimens.
Yes, some patients may experience peripheral neuropathy, including tingling, numbness, or pain in the hands and feet.
Yes, the medicine may lower blood cell counts, requiring regular laboratory monitoring.
Yes, doctors typically recommend blood tests, liver and kidney assessments, and neurological evaluations throughout therapy.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology, hematology, and cancer treatment.